Open AccessCystic Fibrosis Transmembrane Conductance Regulator Modulator Use Is Associated With Reduced Pancreatitis Hospitalizations in Patients With Cystic Fibrosis
Author(s) -
Mitchell L. Ramsey,
Yevgeniya Gokun,
Lindsay A. Sobotka,
Michael Wellner,
Kyle Porter,
Stephen Kirkby,
Susan S. Li,
Georgios I. Papachristou,
Somashekar G. Krishna,
Peter P. Stanich,
Phil A. Hart,
Darwin L. Conwell,
Luis F. Lara
Publication year - 2021
Publication title -
the american journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.907
H-Index - 252
eISSN - 1572-0241
pISSN - 0002-9270
DOI - 10.14309/ajg.0000000000001527
Subject(s) - cystic fibrosis transmembrane conductance regulator , cystic fibrosis , medicine , pancreatitis , rate ratio , gastroenterology , pancreas , pancreatic disease , confidence interval , acute pancreatitis , endocrinology
Acute pancreatitis (AP) occurs among patients with pancreas-sufficient cystic fibrosis (PS-CF) but is reportedly less common among patients with pancreas-insufficient cystic fibrosis (PI-CF). The incidence of AP may be influenced by cystic fibrosis transmembrane conductance regulator (CFTR) modulator use. We hypothesized that CFTR modulators would reduce AP hospitalizations, with the greatest benefit in PS-CF.